Novo Nordisk's Obesity Drug Struggles

This chapter analyzes Novo Nordisk's strategic missteps in the competitive obesity drug market, particularly focusing on their cautious R&D decisions that allowed competitors like Eli Lilly to gain an edge. It delves into the implications of leadership changes and cultural shifts within the company, reflecting on its past successes while facing challenges in reinventing its strategies. Additionally, the chapter addresses the ethical considerations of aggressive marketing and the rising off-label use of obesity drugs, emphasizing the evolving landscape of pharmaceutical development.